STAT9m
Medicare moves to expand coverage for weight-loss drugs Wegovy, Zepbound
The Biden administration is proposing a major expansion of how Medicare and Medicaid cover the weight-loss drugs Wegovy and ...
STAT57m
Amgen drug leads to substantial weight loss in study, but questions remain about competitiveness
An Amgen obesity drug helped participants lose a substantial amount of weight, but questions about how competitive it could ...
STAT4h
Don’t expect Novo-Catalent merger investigation to fizzle out under the new Trump administration
Will the Novo-Catalent merger be challenged under the new Trump administration? A former FTC policy director thinks so.
STAT4h
The disappearance of empathetic touch in medicine
What’s more, the rise of technology in medicine, while beneficial in many ways, has further reduced the use of empathic touch ...
STAT14h
Inside the telehealth-fueled GLP-1 alternative market
The new class of GLP-1 weight loss drugs have been blockbusters since they arrived on the market a few years ago. These ...
STAT5h
Roche immunotherapy fails in lung cancer study, raising questions about drug’s target
A cancer treatment from Roche failed to improve survival in a major lung cancer study, a result that will stoke doubts about ...
STAT7h
An immigration fix to address the health care workforce crisis
Former HHS Secretary Tom Price writes that the new Trump administration should update immigration laws to help the U.S.
STAT14h
Alector Therapeutics’ novel Alzheimer’s strategy fails in Phase 2 trial
Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...
STAT21h
UnitedHealth pays its own physician groups considerably more than others, driving up consumer costs and its profits
First-of-its-kind data analysis finds UnitedHealth Group pays many of its own physician practices significantly more than the ...
STAT19h
Minnesota becomes first state to release report on 340B drug discount program for ‘safety-net’ hospitals
Minnesota has becomes the first state to release a report examining the 340B drug discount program for "safety-net" hospitals ...
STAT18h
Cassava Sciences and its Alzheimer’s drug are done. The damage lingers
The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...
STAT23h
What to make of Trump’s health care nominees
The presumptive new CDC director, Dave Weldon, is a known vaccine safety skeptic. In contrast, the FDA choice — Johns Hopkins ...